CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral ...
CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral ...
CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single ...
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, ...
In June 2022, Qualigen Therapeutics, Inc. QLGN announced it has commenced Investigational New Drug (IND)-enabling studies for its lead therapeutic program, QN-302, which include initial safety and ...
Hosted on MSN
Qualigen Therapeutics Stock Soars 62% After-Hours On BitGo Crypto Deal — Traders Warn Of ‘Bear Day’ Ahead
・Qualigen announced a $30 million partnership with BitGo to manage its C10 digital asset treasury, marking a deeper push into crypto and Web3 under Faraday Future’s ownership. ・The company plans to ...
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Qualigen Therapeutics Inc QLGN was one of the ...
New York, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics Inc. (NASDAQ: QLGN) ("Qualigen", "QLGN" or "Company"), a publicly-trading technology company majority owned by Faraday Future, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results